Fatigue News and Research

RSS

$Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC$

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Amgen today announced that a Phase 3 study evaluating Vectibix (panitumumab) and best supportive care (BSC) met its primary endpoint, demonstrating a statistically significant improvement in overall survival (OS) in patients with chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC) compared to those patients treated with BSC alone.

19 Jun 2015

Novartis presents positive Phase III results of Farydak therapy at EHA

Novartis today presented results from a pivotal Phase III clinical trial exploratory subgroup analysis showing a 7.8-month improvement in median progression-free survival when using Farydak in combination with bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who had received two or more prior regimens, including bortezomib and an immunomodulatory agent.

16 Jun 2015

Vitamin D supplementation may treat Crohn’s disease

New research published in this month’s edition of United European Gastroenterology Journal suggests that supplementation with vitamin D may impact on the intestinal barrier dysfunction associated with Crohn’s disease, and could have a role in the treatment of the condition.

15 Jun 2015

Vitamin D supplementation may affect intestinal barrier dysfunction associated with Crohn's disease

New research published in this month's edition of United European Gastroenterology journal suggests that supplementation with vitamin D may impact on the intestinal barrier dysfunction associated with Crohn's disease, and could have a role in the treatment of the condition.

13 Jun 2015

Switching from Remicade to Inflectra benefits patients with rheumatic diseases

Hospira, Inc., a global leader in biosimilars, today announced the results of an independent clinical study, showing patients with rheumatic diseases experienced comparable clinical effectiveness and safety after switching from Remicade™ to Inflectra.

10 Jun 2015

NASA study explores how the human body responds to stress and fatigue in space

Several Human Research Program investigations are being conducted aboard the International Space Station as part of NASA's One-Year Mission (1YM) to learn more about how the human body responds to stress in a long-duration, low-gravity environment.

10 Jun 2015

Time for a switch for patients with rheumatoid arthritis and ankylosing spondylitis

The comparable safety and efficacy of switching patients to a biosimilar anti-TNF-α monoclonal antibody from the reference medicinal product (RMP) has been further established in data presented at EULAR 2015, the annual meeting of the European League Against Rheumatism.

10 Jun 2015

Updated My MS Manager mobile phone app helps individuals with MS better manage their disease

My MS Manager, the first-of-its kind mobile phone app created by the Multiple Sclerosis Association of America to help individuals with multiple sclerosis (MS) better manage their disease, now offers new features including a way to connect and share information with one's physician.

9 Jun 2015

Merck Canada announces conditional approval of KEYTRUDA (pembrolizumab) for melanoma treatment

Merck Canada Inc. announced today that KEYTRUDATM (pembrolizumab) was authorized for sale with conditions by Health Canada on May 19, 2015. KEYTRUDA is a humanized monoclonal antibody that works by increasing the ability of the body's immune system to fight advanced melanoma, the most serious form of skin cancer. It is the first of a new class of therapies called anti-PD-1s approved in Canada.

8 Jun 2015

Non-invasive prenatal testing can detect maternal cancer at early stage

Non-invasive prenatal testing (NIPT) for chromosomal foetal disorders is used increasingly to test for conditions such as Down's syndrome. NIPT examines DNA from the foetus in the mother's blood, and therefore does not carry the risk of miscarriage involved in invasive testing methods.

7 Jun 2015

Once-weekly Trulicity 0.75 mg shows promising results in Japanese patients with type 2 diabetes

Results from a new study of Japanese patients with type 2 diabetes showed once-weekly Trulicity 0.75 mg provided greater hemoglobin A1c (A1C) reduction compared to once-daily Victoza 0.9 mg after 52 weeks of treatment. Eli Lilly and Company will present these data at the 75th American Diabetes Association Scientific Sessions in Boston.

7 Jun 2015

Severe nonmotor symptom burden common in early Parkinson’s

Almost all patients with early Parkinson’s disease have nonmotor symptoms, with more than a third having a severe burden of symptoms, a study shows.

5 Jun 2015

Ibrutinib (IMBRUVICA) improves survival in treatment-naïve patients with chronic lymphocytic leukemia

Today, Pharmacyclics LLC, an AbbVie company, announced that ibrutinib (IMBRUVICA) improved progression-free survival (PFS; primary endpoint) and multiple secondary endpoints including overall survival (OS) and overall response rate (ORR) in treatment-naïve patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL, respectively) in the final analysis of the Phase III RESONATE™-2 (PCYC-1115) trial.

5 Jun 2015

Cytokinetics, The ALS Association expand partnership to fight against ALS

Cytokinetics, Incorporated and The ALS Association announced an expanded partnership in which the company will provide Gold Level Sponsorship of the National Walks to Defeat ALS as well as Platinum Level Sponsorship for ALS Association Golden West Chapter initiatives.

4 Jun 2015

FDA grants exclusivity to Flublok influenza vaccine for 12 years

Protein Sciences Corporation announced that in a rare move, the FDA is granting exclusivity to Flublok for a period of 12 years. Flublok is the first vaccine awarded this very important status, demonstrating Flublok as a unique and game changing influenza vaccine.

3 Jun 2015

Mary's Place by the Sea - helping women with cancer

Mary’s Place by the Sea is a respite home for women who are receiving treatment for cancer or within one year of post-cancer treatment. They provide services that complement their medical treatment, including oncology massages, individual counseling and nutrition education...

3 Jun 2015

Fatigue News and Research

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Novartis presents positive Phase III results of Farydak therapy at EHA

Vitamin D supplementation may treat Crohn’s disease

Vitamin D supplementation may affect intestinal barrier dysfunction associated with Crohn's disease

Switching from Remicade to Inflectra benefits patients with rheumatic diseases

NASA study explores how the human body responds to stress and fatigue in space

Time for a switch for patients with rheumatoid arthritis and ankylosing spondylitis

Updated My MS Manager mobile phone app helps individuals with MS better manage their disease

Merck Canada announces conditional approval of KEYTRUDA (pembrolizumab) for melanoma treatment

Non-invasive prenatal testing can detect maternal cancer at early stage

Once-weekly Trulicity 0.75 mg shows promising results in Japanese patients with type 2 diabetes

Severe nonmotor symptom burden common in early Parkinson’s

Ibrutinib (IMBRUVICA) improves survival in treatment-naïve patients with chronic lymphocytic leukemia

Cytokinetics, The ALS Association expand partnership to fight against ALS

FDA grants exclusivity to Flublok influenza vaccine for 12 years

Mary's Place by the Sea - helping women with cancer

Survey shows most men with advanced prostate cancer ignore their symptoms as disease progresses

Women who suffer from fibromyalgia benefit from hyperbaric oxygen therapy

ASCO 2015: AMGEN presents new data evaluating less-frequent dosing of kyprolis for multiple myeloma patients

ASCO 2015: AMGEN presents new data evaluating less-frequent dosing of kyprolis for multiple myeloma patients

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News